JP2016128441A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016128441A5 JP2016128441A5 JP2016001684A JP2016001684A JP2016128441A5 JP 2016128441 A5 JP2016128441 A5 JP 2016128441A5 JP 2016001684 A JP2016001684 A JP 2016001684A JP 2016001684 A JP2016001684 A JP 2016001684A JP 2016128441 A5 JP2016128441 A5 JP 2016128441A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- antagonist antibody
- binding portion
- madcam antagonist
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562101877P | 2015-01-09 | 2015-01-09 | |
| US62/101,877 | 2015-01-09 | ||
| US201562263197P | 2015-12-04 | 2015-12-04 | |
| US62/263,197 | 2015-12-04 | ||
| US201562263910P | 2015-12-07 | 2015-12-07 | |
| US62/263,910 | 2015-12-07 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020173121A Division JP7142200B2 (ja) | 2015-01-09 | 2020-10-14 | ＭＡｄＣＡＭアンタゴニストの投与レジメン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016128441A JP2016128441A (ja) | 2016-07-14 |
| JP2016128441A5 true JP2016128441A5 (https=) | 2019-08-29 |
| JP6779621B2 JP6779621B2 (ja) | 2020-11-04 |
Family
ID=55275128
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016001684A Active JP6779621B2 (ja) | 2015-01-09 | 2016-01-07 | ＭＡｄＣＡＭアンタゴニストの投与レジメン |
| JP2020173121A Active JP7142200B2 (ja) | 2015-01-09 | 2020-10-14 | ＭＡｄＣＡＭアンタゴニストの投与レジメン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020173121A Active JP7142200B2 (ja) | 2015-01-09 | 2020-10-14 | ＭＡｄＣＡＭアンタゴニストの投与レジメン |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US10851163B2 (https=) |
| EP (2) | EP4112079A1 (https=) |
| JP (2) | JP6779621B2 (https=) |
| KR (1) | KR102756784B1 (https=) |
| CN (3) | CN107427576A (https=) |
| AU (2) | AU2016205852B2 (https=) |
| BR (1) | BR112017014793A2 (https=) |
| CA (1) | CA2916283C (https=) |
| CL (1) | CL2017001756A1 (https=) |
| EA (1) | EA037288B1 (https=) |
| ES (1) | ES2927958T3 (https=) |
| IL (1) | IL253247B (https=) |
| MA (1) | MA41314A (https=) |
| MX (1) | MX385589B (https=) |
| SG (1) | SG11201705604WA (https=) |
| WO (1) | WO2016110806A2 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6904905B2 (ja) * | 2014-12-24 | 2021-07-21 | ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 抗α４β７インテグリン抗体による治療の結果の予測 |
| CA2916283C (en) * | 2015-01-09 | 2024-07-02 | Pfizer Inc. | MADCAM ANTAGONIST DOSING REGIMEN |
| JP2020521452A (ja) * | 2017-05-24 | 2020-07-27 | パンディオン・セラピューティクス・インコーポレイテッド | 標的化免疫寛容 |
| CN111032694B (zh) | 2017-07-14 | 2024-03-08 | 辉瑞大药厂 | 针对madcam的抗体 |
| CN108118093A (zh) * | 2018-03-06 | 2018-06-05 | 谢琳 | Linc00426在制备骨肉瘤转移诊断产品中的用途 |
| US20210030868A1 (en) * | 2019-07-29 | 2021-02-04 | Cai Gu Huang | Formulation of antibody based drugs for treating lung cancer by inhalation |
| CN113789328A (zh) * | 2021-09-16 | 2021-12-14 | 中国人民解放军海军军医大学 | lncRNA及其在免疫调控及免疫相关疾病诊治中的应用 |
| CN114164211B (zh) * | 2021-09-16 | 2024-02-27 | 中国人民解放军海军军医大学 | lncRNA及其在肿瘤诊断、治疗和预后判断中的应用 |
| CN116631510B (zh) * | 2022-10-28 | 2024-01-12 | 中国人民解放军军事科学院军事医学研究院 | 一种用于鉴别诊断克罗恩病和溃疡性结肠炎的装置 |
| US20240166746A1 (en) | 2022-11-22 | 2024-05-23 | Takeda Pharmaceutical Company Limited | DOSAGE REGIMEN OF MAdCAM-1 ANTIBODY FOR TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US5698679A (en) * | 1994-09-19 | 1997-12-16 | National Jewish Center For Immunology And Respiratory Medicine | Product and process for targeting an immune response |
| US7803904B2 (en) * | 1995-09-01 | 2010-09-28 | Millennium Pharmaceuticals, Inc. | Mucosal vascular addressing and uses thereof |
| US6551593B1 (en) | 1995-02-10 | 2003-04-22 | Millennium Pharmaceuticals, Inc. | Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam |
| WO1998052976A1 (en) | 1997-05-21 | 1998-11-26 | Biovation Limited | Method for the production of non-immunogenic proteins |
| US6217552B1 (en) | 1999-03-01 | 2001-04-17 | Coaxia, Inc. | Medical device for selective intrathecal spinal cooling in aortic surgery and spinal trauma |
| WO2004081049A1 (en) | 2003-03-10 | 2004-09-23 | Auckland Uniservices Limited | Monoclonal antibodies that recognise mucosal addressin cell adhesion molecule-1 (madcam-1), soluble madcam-1 and uses thereof |
| MX350383B (es) | 2004-01-09 | 2017-09-04 | Pfizer | Anticuerpos contra madcam. |
| EP1871806A2 (en) * | 2005-03-08 | 2008-01-02 | Pharmacia & Upjohn Company LLC | ANTI-MAdCAM ANTIBODY COMPOSITIONS |
| EP1904531B1 (en) | 2005-07-08 | 2010-10-06 | Pfizer Limited | Madcam antibodies |
| BRPI0612645A2 (pt) | 2005-07-08 | 2010-11-23 | Pfizer Ltd | uso de anticorpos anti-madcam para o tratamento de doença celìaca e espru tropical |
| WO2007007151A2 (en) | 2005-07-11 | 2007-01-18 | Pfizer Limited | Use of anti-mad-cam antibody for the treatment of emphysema |
| WO2007007159A2 (en) | 2005-07-11 | 2007-01-18 | Pfizer Limited | Anti-madcam antibodies to treat uterine disorders |
| WO2007007160A2 (en) | 2005-07-11 | 2007-01-18 | Pfizer Limited | Anti-madcam antibodies to treat fever |
| WO2007007152A2 (en) | 2005-07-11 | 2007-01-18 | Pfizer Limited | Anti-madcam antibodies to treat metastatic cancers and chloroma |
| US8188235B2 (en) | 2008-06-18 | 2012-05-29 | Pfizer Inc. | Antibodies to IL-6 and their uses |
| DE102010013830A1 (de) * | 2010-03-26 | 2011-09-29 | Carl Zeiss Microlmaging Gmbh | Mikroskop und Verfahren zur mikroskopischen Erfassung von Licht einer Probe |
| KR102175688B1 (ko) | 2013-03-27 | 2020-11-06 | 제넨테크, 인크. | 베타7 인테그린 길항제를 사용하는 위장 염증성 장애의 치료를 평가하기 위한 바이오마커의 사용 |
| CA2916283C (en) * | 2015-01-09 | 2024-07-02 | Pfizer Inc. | MADCAM ANTAGONIST DOSING REGIMEN |
-
2015
- 2015-12-23 CA CA2916283A patent/CA2916283C/en active Active
-
2016
- 2016-01-05 MA MA041314A patent/MA41314A/fr unknown
- 2016-01-06 CN CN201680014443.3A patent/CN107427576A/zh active Pending
- 2016-01-06 CN CN202111331779.1A patent/CN114732899A/zh active Pending
- 2016-01-06 WO PCT/IB2016/050047 patent/WO2016110806A2/en not_active Ceased
- 2016-01-06 AU AU2016205852A patent/AU2016205852B2/en active Active
- 2016-01-06 MX MX2017009047A patent/MX385589B/es unknown
- 2016-01-06 US US15/542,110 patent/US10851163B2/en active Active
- 2016-01-06 SG SG11201705604WA patent/SG11201705604WA/en unknown
- 2016-01-06 KR KR1020177021819A patent/KR102756784B1/ko active Active
- 2016-01-06 EP EP22179107.2A patent/EP4112079A1/en active Pending
- 2016-01-06 CN CN202111331776.8A patent/CN114377125A/zh active Pending
- 2016-01-06 EA EA201791227A patent/EA037288B1/ru unknown
- 2016-01-06 EP EP16702586.5A patent/EP3242684B1/en active Active
- 2016-01-06 BR BR112017014793A patent/BR112017014793A2/pt not_active Application Discontinuation
- 2016-01-06 ES ES16702586T patent/ES2927958T3/es active Active
- 2016-01-07 JP JP2016001684A patent/JP6779621B2/ja active Active
-
2017
- 2017-06-29 IL IL253247A patent/IL253247B/en unknown
- 2017-07-03 CL CL2017001756A patent/CL2017001756A1/es unknown
-
2020
- 2020-10-14 JP JP2020173121A patent/JP7142200B2/ja active Active
- 2020-11-30 US US17/107,228 patent/US11884726B2/en active Active
-
2021
- 2021-10-12 AU AU2021250850A patent/AU2021250850B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016128441A5 (https=) | ||
| US12018086B2 (en) | Kit comprising contiguous nucleobases, including position 76, of RS5745994 | |
| JP7177868B2 (ja) | 乾癬性関節炎の疾患活動性を評価するためのバイオマーカーおよび方法 | |
| JP2023002583A (ja) | Ｉｌ２３経路バイオマーカーを使用するｉｌ２３アンタゴニストに対する臨床応答の予測 | |
| Colman et al. | Antibodies‐to‐infliximab accelerate clearance while dose intensification reverses immunogenicity and recaptures clinical response in paediatric Crohn’s disease | |
| Kneepkens et al. | Lower etanercept levels are associated with high disease activity in ankylosing spondylitis patients at 24 weeks of follow-up | |
| FI3536710T3 (fi) | Anti-il-36r -vasta-aineita | |
| JP2015504430A (ja) | Ｉｌ−７アンタゴニスト及びｐｓａ応答又は非応答対立遺伝子を用いた乾癬性関節炎（ｐｓａ）を治療する方法 | |
| RU2014106658A (ru) | Новое антитело к cxcr4 и его применение для выявления и диагностики рака | |
| Van Stappen et al. | Validation of a sample pretreatment protocol to convert a drug‐sensitive into a drug‐tolerant anti‐infliximab antibody immunoassay | |
| JP2016502091A5 (https=) | ||
| Higham et al. | Increased mast cell activation in eosinophilic chronic obstructive pulmonary disease | |
| JP2019508370A (ja) | Ｉｌ２３アンタゴニストに対する臨床応答の予測因子としてのｃｃｌ２０ | |
| JP2018504584A (ja) | 過敏性腸疾患患者を治療するためのベドリズマブの投与計画を確立する方法 | |
| Dreesen et al. | Pharmacokinetic modeling and simulation of biologicals in inflammatory bowel disease: the dawning of a new era for personalized treatment | |
| Berger et al. | Comparison of immunoassays for measuring serum levels of golimumab and antibodies against golimumab in ulcerative colitis: a retrospective observational study | |
| Hsu et al. | Serum viral load at the virological relapse predicts subsequent clinical flares in chronic hepatitis B patients off entecavir therapy | |
| Song et al. | Population pharmacokinetic model for the use of intravenous or subcutaneous infliximab in patients with inflammatory bowel disease: real-world data from a prospective cohort study | |
| Pisani et al. | Proteomic insights on the metabolism in inflammatory bowel disease | |
| Eder et al. | Trefoil factor-3 is not a useful marker of mucosal healing in Crohn's disease treated with anti-TNF-α antibodies | |
| US20250208140A1 (en) | Hbv diagnostic, prognostic, and therapeutic methods and products | |
| US20240118278A1 (en) | Hbv diagnostic, prognostic, and therapeutic methods and products | |
| Yang et al. | Serum CDC42 is increased during tumor necrosis factor inhibitor treatment, and its elevation correlates with satisfactory treatment response in rheumatoid arthritis patients | |
| Rashid et al. | VEGF subtype A and B gene expression, clues to a temporal signature in Kawasaki disease, implications for coronary pathogenesis through a secondary analysis of clinical datasets | |
| Li et al. | A Risk Prediction Model for the Development of Rheumatoid Arthritis, Sjögren's Syndrome, Systemic Sclerosis in Patients With Systemic Lupus Erythematosus: Multicenter Approaches |